All stock lists
Genmab A/S (NASDAQ:GMAB)
DK · Delayed Price · Currency is USD
Healthcare · Biotechnology
57.29+12.62 (+28.25%)
Market cap
$35.2B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 1, 2009
Website
Insider Score
––Not scored
GMAB Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
GMAB analyst forecast
GMAB analyst consensus
Moderate Buy5 ratings
Buy 5 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
GMAB 12-month price target
$50.00-12.7% downsideaverage of 2 firms
$58.00High
$42.00Low
GMAB ratings mix, last 12 months
Buy Hold Sell
Best analysts covering GMAB
- Guggenheim100%success rate · +19.6% avg return · 2 calls
- Truist Securities33%success rate · -11.3% avg return · 9 calls
- HC Wainwright & Co.31%success rate · -9.0% avg return · 48 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
GMAB analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | TD Cowen | Buy | — | — | Reiterated | 2026-10-26 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2026-10-26 |
| Morgan Stanley | — | $42.00 | +9.1% | — | 2026-10-20 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-07 |
| Guggenheim | Buy | $58.00 | +53.4% | Reiterated | 2026-10-07 | |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-10-07 |
| Guggenheim | Buy | $54.00 | +55.4% | Reiterated | 2026-10-05 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-14 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-08-07 |
| — | TD Cowen | Buy | — | — | Upgraded | 2026-07-22 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-04-30 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-02-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-02-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-10 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-11-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-02 |
| — | Guggenheim | Buy | — | — | Upgraded | 2025-09-24 |
| — | Guggenheim | Buy | — | — | Upgraded | 2025-09-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-08-15 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-07-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-05-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-09 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-03-11 |
| — | William Blair | Outperform | — | — | Upgraded | 2025-03-11 |
| — | Leerink Partners | Outperform | — | — | Upgraded | 2025-02-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-22 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-08 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-11-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-13 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2024-09-11 |
| — | Truist Securities | Buy | — | — | Reiterated | 2024-09-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-27 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-20 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2024-08-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-07-18 |
| — | RBC Capital | Outperform | — | — | Upgraded | 2024-07-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-06-27 |
| — | BTIG | Buy | — | — | Reiterated | 2024-06-27 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-06-20 |
| — | Truist Securities | Buy | — | — | Reiterated | 2024-06-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-06-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-04-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-04-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-27 |
| — | Morgan Stanley | Underweight | — | — | Reiterated | 2024-03-26 |
| — | Truist Securities | Buy | — | — | Reiterated | 2024-03-26 |
GMAB earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2025-11-06 | 0.48 | 0.65 | $1.01B | $1.02B |
| 2026-02-17 | 0.46 | 0.05 | $1.07B | $1.06B |
| 2026-05-07 | 0.15 | 0.09 | $905.8M | $896.0M |
| 2026-08-06 | 0.37 | 0.54 | $1.12B | $1.16B |
| 2026-11-05Upcoming | 0.37 | — | $1.20B | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.